With intense pressure placed upon the biopharmaceutical industry to rapidly develop and produce COVID-19 vaccines, diagnostics and therapeutics, it is imperative that CDMOs adapt to ensure they can deal with the increased demand and existing commitments.
In this roundtable, Bill Vincent, Genezen Founder, provides insight into how COVID-19 has accelerated demand for clinical products and outlines how CDMOs are dealing with this pressure despite constraints on the supply of raw materials as well as manufacturing capacity issues.
